OBJECTIVES: The aim of the present study was to investigate the activity of CMP-NeuAc:Galbeta(1,4)GlcNAc sialyltransferase (ST6Gal I) in colorectal cancer (CRC). METHODS: ST6Gal I activity was determined in healthy, transitional and tumor tissues from the same patient using asialotransferrin and N-acetyllactosamine as acceptors. RESULTS: ST6Gal I activities with asialotransferrin (n = 85) and N-acetyllactosamine (n = 40) as acceptors were statistically significantly enhanced in CRC tissue compared with healthy mucosa from the same patient (p = 0.001). Using transitional tissue (n = 27), enhancement versus healthy tissue was observed (p < 0.05). A positive correlation was found between ST6Gal I activity with N-acetyllactosamine and asialotransferrin in healthy (n = 32), tumorous (n = 32) and transitional tissue (n = 27), supporting the fact that the same enzyme was detected using both acceptors. Furthermore, we studied the relationship between some patients' clinicopathological features and ST6Gal I activity. Although the differences were not statistically significant, the levels of ST6Gal I activity in tumorous and transitional tissues varied with the histological grade of the tumor; however, we failed to find a correlation with the AJCC tumor classification. CONCLUSIONS: This work reports enhanced ST6Gal I activity in tumor and transitional tissues from CRC patients. However, our overall results suggest that ST6Gal I activity is not indicative of the patient's outcome.
OBJECTIVES: The aim of the present study was to investigate the activity of CMP-NeuAc:Galbeta(1,4)GlcNAc sialyltransferase (ST6Gal I) in colorectal cancer (CRC). METHODS:ST6Gal I activity was determined in healthy, transitional and tumor tissues from the same patient using asialotransferrin and N-acetyllactosamine as acceptors. RESULTS:ST6Gal I activities with asialotransferrin (n = 85) and N-acetyllactosamine (n = 40) as acceptors were statistically significantly enhanced in CRC tissue compared with healthy mucosa from the same patient (p = 0.001). Using transitional tissue (n = 27), enhancement versus healthy tissue was observed (p < 0.05). A positive correlation was found between ST6Gal I activity with N-acetyllactosamine and asialotransferrin in healthy (n = 32), tumorous (n = 32) and transitional tissue (n = 27), supporting the fact that the same enzyme was detected using both acceptors. Furthermore, we studied the relationship between some patients' clinicopathological features and ST6Gal I activity. Although the differences were not statistically significant, the levels of ST6Gal I activity in tumorous and transitional tissues varied with the histological grade of the tumor; however, we failed to find a correlation with the AJCC tumor classification. CONCLUSIONS: This work reports enhanced ST6Gal I activity in tumor and transitional tissues from CRC patients. However, our overall results suggest that ST6Gal I activity is not indicative of the patient's outcome.
Authors: Marta Pérez-Garay; Beatriz Arteta; Lluís Pagès; Rafael de Llorens; Carme de Bolòs; Fernando Vidal-Vanaclocha; Rosa Peracaula Journal: PLoS One Date: 2010-09-01 Impact factor: 3.240
Authors: Katie L Alexander; Carolina A Serrano; Asmi Chakraborty; Marie Nearing; Leona N Council; Arnoldo Riquelme; Marcelo Garrido; Susan L Bellis; Lesley E Smythies; Phillip D Smith Journal: J Biol Chem Date: 2020-08-06 Impact factor: 5.157
Authors: Kaitlyn A Dorsett; Michael P Marciel; Jihye Hwang; Katherine E Ankenbauer; Nikita Bhalerao; Susan L Bellis Journal: Glycobiology Date: 2021-06-03 Impact factor: 4.313